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ABSTRACT
Purpose. Considering the comparable prognosis in early-
stage breast cancer after breast-conserving therapy (BCT)
and mastectomy, quality of life should be a focus in
treatment decision(s). We retrospectively collected PROs
and analyzed differences per type of surgery delivered. We
aimed to obtain reference values helpful in shared decision-
making.
Patients and Methods. pTis-T3N0-3M0 patients operated
between January 2005 and September 2016 were eligible
if: (1) no chemotherapy was administered\ 6 months prior
to enrolment, and (2) identical surgeries were performed in
case of bilateral surgery. After consent, EQ-5D-5L,
EORTC-QLQ-C30/BR23, and BREAST-Q were adminis-
tered. PROs were evaluated per baseline characteristics
using multivariable linear regression models. Outcomes
were compared for different surgeries as well as for pri-
mary (PBC) and second primary or recurrent (SBC) breast
cancer patients using analyses of variance (ANOVAs).
Results. The response rate was 68%. PROs in 612 PBC
patients were comparable to those in 152 SBC patients.
Multivariable analyses showed increasing age to be asso-
ciated with lower ‘‘physical functioning’’ [b - 0.259,
p\ 0.001] and ‘‘sexual functioning’’ [b - 0.427,
p\ 0.001], and increasing time since surgery with less
‘‘fatigue’’ [b - 1.083, p\ 0.001]. Mastectomy [b
- 13.596, p = 0.003] and implant reconstruction [b
- 13.040, p = 0.007] were associated with lower ‘‘satis-
faction with breast’’ scores than BCT. Radiation therapy
was associated with lower satisfaction scores than absence
of radiotherapy.
Discussion. PRO scores were associated with age, time
since surgery, type of surgery, and radiation therapy in
breast cancer patients. The scores serve as a reference
value for different types of surgery in the study population
and enable prospective use of PROs in shared decision-
making.
Breast cancer is the most frequently diagnosed cancer in
women.1 In The Netherlands, 1 in 7 women are diagnosed
with breast cancer.2 Favorable high survival rates are
reported eminently in early stages.3 Survivorship as well as
physical, sexual, and psychosocial consequences of breast
cancer therapies should therefore be accounted for in
treatment decision-making. In early-stage breast cancer,
high survival rates are achieved irrespective of type of
surgery, whether breast-conserving therapy (BCT; breast-
conserving surgery with breast radiation therapy) or mas-
tectomy (with or without reconstruction).4–6 Consequently,
anticipation of outcomes reflecting physical, sexual, and
psychosocial functioning is very important in treatment
decision-making in these patients.
Value in healthcare is defined as the health outcome per
total cost. Multiple health outcomes are often used for one
medical condition to define this value.7 In value-based
healthcare (VBHC), the defined outcomes are patient
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oriented and therefore form a combination of more tradi-
tional clinical outcomes (for example, oncological outcome
or complication rates) and patient-reported outcomes
(PROs). Collaborations of the International Consortium for
Health Outcomes Measurement (ICHOM) with several
other healthcare institutions worldwide have resulted in the
development of a standard breast cancer outcome set.8
Incorporation of this set is expected to pave the way
towards value-based breast cancer care with application in
shared decision-making as well as follow-up.
Patient-reported outcome measures (PROMs) are pivotal
in the ICHOM breast cancer outcome set, accounting for
approximately 75% of outcomes, the other 25% being
related to clinical outcomes. Little is known about PROM
scores following different surgeries in relation to differ-
ences in patient, tumor, and systemic or radiation treatment
characteristics. Our institute implemented a breast cancer
outcome set embedded in the institutional VBHC initiative
in October 2015. At predetermined time points, breast
cancer patients received digitalized PRO questionnaires
prior to their routine visit at the outpatient clinic. PROs
were evaluated with the patient at the outpatient clinic and
used to improve individual care.9 Consequently, there was
an urgent need to propose valid and meaningful reference
scores. It was hypothesized that PROs differ between sur-
gical treatments. The aim of this study is to assess the
correlation between PROs and patient, tumor, and treat-
ment characteristics and to provide PRO reference values
for different breast cancer surgeries. We therefore collected
PROs amongst breast cancer patients operated in the last
10 years within our institute.
PATIENTS AND METHODS
Study Population
Ethical approval was granted by the Institutional Review
Board of the Erasmus Medical Centre (Erasmus MC),
Rotterdam, The Netherlands (MEC-2015-669). Patients
who had undergone breast cancer surgery between January
2005 and September 2016 were identified from electronic
patient files using operation codes. Women aged
[ 18 years with pTis-3N0-3M0 breast cancer were
deemed eligible. Patients were excluded if they had been
treated with chemotherapy within 6 months prior to the
PRO assessment or had bilateral breast surgery with dif-
ferent types of surgery performed per side.
Procedures
This cross-sectional study retrospectively reviewed
medical records to compile the following data: age, date
and type of breast surgery, tumor morphology, tumor–
node–metastasis (TNM) staging according to the TNM
classification system (7th edition),10 hormonal receptor
status, human epidermal growth factor receptor 2 (HER2)
status, BRCA1/2 status, local recurrence, second primary
breast cancer, and details regarding chemotherapy and/or
immunotherapy and endocrine therapy. Time since surgery
was defined as time between first surgery and questionnaire
completion. The respondents were categorized into those
with ‘‘primary breast cancer’’ (PBC) and ‘‘second primary
or recurrent breast cancer’’ (SBC). PBC patients repre-
sented women with primary unilateral or bilateral breast
cancer, while SBC patients represented women with local
recurrence or second primary breast cancer. In case of
breast cancer recurrence or second primary breast cancer,
data regarding patient age, tumor morphology, and TNM
stage of the primary diagnosis was used.
Operation types defined were: breast-conserving therapy
(BCT), mastectomy alone (MAS), mastectomy followed by
immediate or delayed implant reconstruction (REC I), and
mastectomy followed by immediate or delayed autologous
reconstruction (REC A). Nodal stage at primary diagnosis
was categorized as N0, N ? (N1–3), or unknown. Adjuvant
systemic therapy was categorized as: (1) no systemic
therapy, (2) chemotherapy and/or immunotherapy (CTx),
(3) endocrine therapy (ETx), (4) chemotherapy/im-
munotherapy and endocrine therapy (CTx & ETx), or (5)
unknown. Radiotherapy was categorized as (1) radiation
therapy following breast-conserving surgery, (2) no radia-
tion therapy, or (3) thoracic wall radiotherapy in case of
mastectomy and/or locoregional radiotherapy in case of
mastectomy or BCT.
Eligible women were contacted by telephone to request
their participation. Upon oral informed consent, details on
adjuvant therapy and last breast surgery were verified.
Patients who did not answer were called up to six times,
after which participation was no longer pursued.
Following consent, four questionnaires were adminis-
tered; Euro-QoL 5D-5L (EQ-5D-5L version 2.0).11 The
European Organization of Research and Treatment of
Cancer quality of life questionnaires (EORTC-QLQ-C30
version 3.012 and EORTC-QLQ-BR23 version 1.013), and
BREAST-Q (postoperative version 1.0).14 The question-
naires used are proposed in the ICHOM breast cancer
outcome set to evaluate breast cancer patients undergoing
locoregional treatment(s).8 The EORTC-QLQ-C30 is a
generic oncologic questionnaire containing 30 questions
with 6 single-item scores, 9 multiitem scales, 3 symptom
scales, and an additional global health status/quality of life
(QoL) scale.15 The EORTC-QLQ-BR23 is a breast cancer-
specific questionnaire of the EORTC QLG that contains 23
questions made up of 8 multiple-item scales and is con-
sidered an addition to the EORTC-QLQ-C30 specifically
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for breast cancer patients. The BREAST-Q is a surgery-
specific questionnaire proposed in the ICHOM set to
measure ‘‘satisfaction with breast’’ following breast cancer
surgery. Multiitem domains are, however, also available to
evaluate ‘‘satisfaction with overall outcome,’’ ‘‘psychoso-
cial well-being,’’ ‘‘sexual well-being,’’ ‘‘physical well-
being,’’ and ‘‘satisfaction with care.’’14 In the current study,
all modules of the BREAST-Q except ‘‘satisfaction with
overall outcome’’ were used.
Patients were given the choice of internet-based ques-
tionnaires sent by email or paper-based questionnaires sent
by mail (with postage-paid return envelope). If the ques-
tionnaires remained uncompleted, a weekly reminder up to
3 weeks was sent by email (internet-based). After 4 weeks
of no response, patients were contacted by telephone and
requested to complete questionnaires (internet-based and
paper-based). Thereafter, response was no longer actively
pursued. PRO scores were calculated according to ques-
tionnaire scoring manual. PROs were evaluated for patients
who completed at least the EORTC-QLQ-C30
questionnaire.
Study Outcomes
The primary aim was to obtain reference values for
PROs following different surgical strategies in relation to
patient, tumor, and treatment characteristics of PBC
patients. Additionally, PROs of SBC patients were evalu-
ated and compared with PROs of PBC patients.
Statistical Analysis
All analyses were performed using SPSS Statistics for
Windows (version 21.0). Baseline characteristics were
compared for responders versus nonresponders and PBC
versus SBC patients. The different surgical groups were
compared within both PBC and SBC using one-way
ANOVA. Post hoc analyses were performed to detect dif-
ferences between specific groups. To evaluate the effect of
patient, tumor, and treatment on PROs, a multivariate lin-
ear regression was used in PBC patients. Factors evaluated
were age, time since surgery, uni/bilateral breast cancer,
BRCA mutation status, tumor stage, nodal stage, systemic
therapy status, and radiotherapy status. Beta coefficients
(b) with corresponding p-values were calculated for the
index value (EQ-5D-5L), ‘‘global health status’’/‘‘physical
functioning’’/‘‘role functioning’’ (EORTC-QLQ-C30),
‘‘body image’’/‘‘sexual functioning’’ (EORTC-QLQ-
BR23), and ‘‘Q-satisfaction with breast’’/‘‘Q-physical’’/
‘‘Q-psychosocial,’’ and ‘‘Q-sexual’’ (BREAST-Q). p values
B 0.01 were considered statistically significant.
RESULTS
Out of 1850 patients identified, 1230 (66.5%) had pTis-
T3N0-3M0 breast cancer at primary diagnosis. A total of
1116 (90.7%) were eligible for participation (Fig. 1). Of
the eligible patients, 764 (68.5%) responded. Of 352 non-
responders, 114 (40.9%) could not be reached, 162 (46%)
declined participation, and 46 (13.1%) did not complete the
EORTC-QLQ-C30.
Study Population
Responders Versus Nonresponders Responders were
significantly younger compared with nonresponders (50.5
vs 52.4 years, p = 0.04). Significant differences were
additionally found for type of surgery performed, T
stage, and systemic and radiation therapy (Supplementary
Table S1).
Responders: Baseline Characteristics and Treatment A
total of 612 (80.1%) responders had PBC (Table 1), and
152 (19.9%) women had SBC (Supplementary Table S2).
Of PBC patients, 257 (41.9%) underwent BCT, 162
(26.6%) mastectomy, 110 (17.9%) implant reconstruction,
and 83 (13.5%) autologous reconstruction (Table 1). PBC
patients showed significant differences between the
surgical groups for age, time since surgery,
unilateral/bilateral surgery, T-stage, N-stage, systemic
therapy, radiation therapy, and BRCA mutation status
(Table 1).
Patient-Reported Outcomes
Completion rates for the individual PRO modules in
respondents ranged between 88 and 100%, with the
exception of the Q-sexual module, which showed lower
response rates (Table 2, Supplementary Table S3). Statis-
tically significant differences between surgical treatments
were found in the PBC group in ‘‘physical functioning,’’
‘‘sexual functioning,’’, and all Q-scores on univariate
analyses (Table 2). Post hoc analyses showed that mas-
tectomy patients overall reported significantly lower mean
scores on ‘‘physical functioning’’ (80.1) compared with
BCT (86.4, p = 0.001), compared with implant (92.6,
p\ 0.001), and compared with autologous reconstruction
(87.5, p = 0.006). ‘‘Body image’’ was lower following
mastectomy (75.7) compared with BCT (83.9, p = 0.005).
Significantly lower ‘‘sexual functioning’’ scores (EORTC-
QLQ-BR23) were reported by BCT patients (24.2) com-
pared with implant (36.6, p\ 0.001) and autologous
reconstruction (33.6, p = 0.001) patients. Lower mean
‘‘sexual functioning’’ scores were also reported by mas-
tectomy patients (20.6) compared with both implant and
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autologous reconstruction patients (p\ 0.001 and
p = 0.001, respectively). ‘‘Q-psychosocial’’ was lower
following mastectomy (65.8) compared with implant (74.1,
p = 0.004) and autologous reconstruction (75.7,
p\ 0.001). Mean ‘‘Q-satisfaction with breast’’ reported by
mastectomy patients (61.7) was significantly lower com-
pared with BCT (65.7, p = 0.006) and autologous
reconstruction patients (70.5, p = 0.004). No significant
differences in outcome were found between the different
surgeries in the SBC group (data not shown).
When evaluating PROs in multivariate analyses,
increasing age was related to lower scores on ‘‘physical
functioning’’ (b - 0.259, p\ 0.001) and ‘‘sexual func-
tioning’’ (b - 0.427, p\ 0.001) (Table 3). Longer time
since surgery was associated with less ‘‘fatigue’’ (b
- 1.083, p\ 0.001) (Supplementary Table S4). ‘‘Q-satis-
faction with breast’’ was significantly lower for patients
following mastectomy (b - 13.596, p = 0.003) and
implant reconstruction (b - 13.040, p = 0.007) compared
with BCT (Table 3). If patients had not undergone radia-
tion therapy, ‘‘Q-satisfaction with breast’’ was significantly
better than following BCT (with consequent radiation
therapy) (b 11.956, p\ 0.009) (Table 3).
DISCUSSION
Breast cancer patients are faced with complex treatment
decision(s) shortly after breast cancer diagnosis. Insights
into not only prognosis but also quality of life or daily
functioning resulting from these decisions could improve
the shared decision-making process and ultimately the care
delivered. Knowledge on QoL related to different surgical
treatments is urgently needed. The aim of this study is to
obtain and evaluate PROs in breast cancer patients
according to the surgery performed. Collected PROs
indeed showed statistically significant differences for the
various surgeries performed. The collected PROs can serve
as reference and ultimately pave the way for implementa-
tion of value-based healthcare among future breast cancer
patients at the outpatient clinic.
In primary breast cancer patients, PRO scores in mas-
tectomy patients were lower compared with BCT or breast
reconstruction patients, except for ‘‘Q-physical’’ and ‘‘Q-
satisfaction with breast.’’ Both mastectomy patients and
patients with implant reconstruction reported significantly
lower ‘‘satisfaction with breast’’ scores compared with
BCT or autologous reconstruction patients. These results
corroborate previous studies which showed lower
1,230
Tis-T3N0-3M0
Operated breast cancer patients
1,116
Eligible patients
352 non respondents:
764 respondents
612 152
Tis-T3N0-3M0
Excluded:
-33 (2.6%) Systemic therapy < 6 months
-12 (0.9%) Other malignancies of the breast
-69 (5.4%) Different surgery for each breast
-144 (40.9%) Unreachable
-162 (46.0%) Refused to participate
-46 (13.1%) Questionnaires remainded uncompleted
PBC patients Nono-PBC patients
FIG. 1 Flowchart of study
selection process. T tumor stage,
N nodal stage, PBC primary
breast cancer, SBC second
primary or recurrent breast
cancer
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TABLE 1 Baseline characteristics of 612 primary breast cancer patients per type of surgery, n (%)
All n = 612 BCT n = 257 MAS n = 162 REC I n = 110 REC A n = 83 p value§
Median (IQR) age (years) 51.0 (43.0–60.0) 54.0 (48.0–62.0) 55.0 (47.0–63.0) 42.5 (36.0–51.0) 45.0 (37.0–52.0) \ 0.001¥
Median (IQR) time since surgery (years) 6.3 (3.3–9.4) 5.3 (2.8–8.1) 7.1 (3.7–9.8) 7.0 (3.7–10.4) 7.2 (4.7–9.5) \ 0.001¥
Surgery \ 0.001
Unilateral 475 (77.6) 251 (97.7) 133 (82.1) 51 (46.4) 40 (48.2)
Bilateral 137 (22.4) 6 (2.3) 29 (17.9) 59 (53.6) 43 (51.8)
Unknown .0 .0 .0 .0 .0
T stage \ 0.001
T1 354 (57.8) 173 (67.3) 86 (53.1) 58 (52.7) 39 (47.0)
T2 128 (20.9) 42 (16.3) 51 (31.5) 14 (12.7) 21 (25.3)
T3 18 (2.9) .0 8 (4.9) 4 (3.6) 6 (7.2)
CIS 108 (18.0) 42 (16.3) 17 (10.5) 33 (30.0) 16 (19.3)
Unknown 2 (0.3) .0 .0 1 (0.9) 1 (1.2)
N stage \ 0.001
N0 442 (72.2) 211(82.1) 91 (56.2) 90 (81.8) 50 (60.2)
N? 170 (27.8) 46 (17.9) 71 (43.8) 20 (18.2) 33 (39.8)
Unknown .0 .0 .0 .0 .0
Systemic therapy \ 0.001
None 256 (41.8) 130 (50.6) 46 (28.4) 53 (48.2) 27 (32.5)
CTx 88 (14.4) 26 (10.1) 20 (12.3) 16 (14.5) 25 (30.1)
ETx 95 (15.5) 49 (19.1) 34 (21.0) 10 (9.1) 2 (2.4)
CTx & ETx 173 (28.3) 52 (20.2) 62 (38.3) 31 (28.2) 29 (34.9)
Unknown .0 .0 .0 .0 .0
Radiation therapy \ 0.001
RTx following BCS 233 (38.1) 233 (90.7) .0 .0 .0
No RTx 293 (47.9) 14 (5.4) 120 (74.1) 94 (85.5) 65 (78.3)
Thoracic-wall and/or locoregional RTx 85 (13.9) 9 (3.5) 42 (25.9) 16 (14.5) 18 (21.7)
Unknown 1 (0.2) 1 (0.4) .0 .0 .0
BRCA \ 0.001
BRCA1/2 negative 399 (65.2) 179 (69.6) 113 (69.8) 58 (52.7) 49 (59.0)
BRCA1/2 positive 90 (14.7) 13 (5.1) 15 (9.3) 36 (32.7) 26 (31.3)
Unknown 123 (20.1) 65 (25.3) 34 (20.9) 16 (14.6) 8 (9.6)
Histological type 0.003
IDC 415 (67.8) 185 (72.0) 113 (69.8) 58 (52.7) 59 (71.1)
ILC 44 (7.2) 16 (6.2) 16 (9.9) 7 (6.4) 4 (4.8)
CIS 111 (18.2) 41 (16.0) 19 (11.7) 35 (31.8) 16 (19.3)
Other 35 (5.7) 15 (5.8) 12 (7.4) 7 (6.4) 2 (2.4)
Unknown 7 (1.1) .0 2 (1.2) 3 (2.7) 2 (2.4)
Differentiation grade^ \ 0.001
Grade 1 100 (16.3) 61 (23.7) 21 (13.0) 11 (10.0) 7 (8.4)
Grade 2 216 (35.3) 100 (38.9) 63 (38.9) 31 (28.2) 20 (24.1)
Grade 3 160 (26.1) 49 (19.1) 55 (34.0) 24 (21.8) 32 (38.6)
NA 113 (18.5) 44 (17.1) 19 (11.7) 35 (31.8) 16 (19.3)
Unknown 23 (3.8) 3 (1.2) 4 (2.5) 9 (8.2) 8 (9.6)
BCT breast-conserving therapy, MAS mastectomy, REC I mastectomy followed by (in)direct implant reconstruction, REC A mastectomy followed by
(in)direct autologous reconstruction, CTx chemotherapy and/or immunotherapy, ETx endocrine therapy, RTx radiation therapy, IDC invasive ductal
carcinoma, ILC invasive lobular carcinoma, CIS carcinoma in situ
§Chi squared test
¥Kruskall–Wallis test
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satisfaction and impaired sexual, psychosocial, and physi-
cal functioning following mastectomy compared with BCT
or breast reconstruction.16,17 After adjustment for patient,
tumor, and treatment characteristics, a significant effect of
surgical treatment on ‘‘Q-satisfaction with breast’’ scores
persisted. Compared with BCT, statistically significant
lower ‘‘Q-satisfaction with breast’’ was reported by mas-
tectomy and implant reconstruction patients. No
statistically significant differences were found in PROs
between autologous reconstruction and BCT when adjust-
ing for patient, tumor, and treatment characteristics.
Contradictory results are found in literature, reporting
comparable PRO scores18 or scores in favor of autologous
reconstruction techniques.16 ‘‘No radiation therapy’’ was
associated with statistically significant higher ‘‘Q-satisfac-
tion with breast’’ scores as compared with BCT patients.
Thoracic wall radiation therapy (25.9, 14.5, and 21.7% of
mastectomy, REC I, and REC A patients, respectively) and
locoregional radiotherapy in 3.5% of the BCT patients was
associated with lower Q-satisfaction scores compared with
patients who had not undergone radiation therapy. Radia-
tion therapy is therefore an important independent factor
for ‘‘Q-satisfaction with breast’’ scores in addition to the
type of surgery performed.
Strengths of the current study include the size of the
study population and the response rate of 68%. This
enabled evaluation of four different PROMs, generating a
detailed reflection of quality of life. To the best of the
authors’ knowledge, this is the largest study to evaluate the
complete set of PROs proposed in the ICHOM breast
cancer set per type of surgery with adjustment for potential
confounders. This is a pivotal step forward towards
extensive use of PROMs in clinical research and practice
for implementation of VBHC. It furthermore enables future
international comparison. When both PROs and baseline
characteristics are available, case-mix-corrected compar-
ison between centers can be performed to benchmark.
Limitations include the single-center and retrospective
design. Longitudinal PRO collection is proposed when
using these outcomes as a clinical tool. Enabling compar-
ison with baseline values is expected to reflect the influence
of different treatments better than a single score obtained
following treatment. Moreover, not all variables that pos-
sibly affect PROs were available for the current cohort,
such as socioeconomic status.16 Large multicenter initia-
tives are needed to obtain narrow reference scores as well
as the possibility for benchmarking. Evaluation of PROs
obtained in retrospect does however generate the necessary
insights into factors possibly related to PRO scores. These
TABLE 2 Mean (SD) PRO scores per type of surgery in 612 primary breast cancer patients, n (%)
BCT (n = 257) MAS (n = 162) REC I (n = 110) REC A (n = 83) p value¥
EQ-5D-5L
Index value 0.83 (0.14) [93] 0.81 (0.16) [96] 0.86 (0.15) [98] 0.85 (0.14) 0.036
EORTC-QLQ-C30
Global health status 79.7 (17.5) 76.2 (19.5) 82.6 (18.6) 81.3 (17.5) 0.026
Physical function 86.4 (14.4) 80.1 (19.6) 92.6 (9.8) 87.5 (14.6) \ 0.001*
Role function 85.0 (21.3) 78.0 (26.0) 86.2 (22.7) 83.7 (24.0) 0.01
Fatigue± 25.6 (25.0) 28.7 (24.1) 21.0 (23.0) 24.4 (25.3) 0.09
Pain± 16.6 (21.0) 20.9 (26.6) 13.2 (19.2) 16.1 (22.3) 0.042
EORTC-QLQ-BR23
Body image 83.9 (21.3) [99] 75.7 (26.0) [97] 77.3 (25.1) [90] 81.9 (21.0) [95] 0.003*
Sexual function 24.2 (20.8) [95] 20.6 (22.3) [91] 36.6 (24.0) [89] 33.6 (24.1) [90] \ 0.001*
BREAST-Q
Physical well-being 71.2 (18.9) [96] 75.1 (19.2) [98] 76.8 (10.9) [96] 78.3 (13.8) [98] 0.002*
Psychosocial well-being 70.1 (21.4) [96] 65.8 (18.8) [98] 74.1 (20.1) [96] 75.7 (17.5) [98] 0.001*
Satisfaction with breasts 65.7 (22.4) [95] 61.8 (17.7) [96] 61.2 (15.7) [96] 70.5 (20.2) [98] 0.003*
Sexual well-being 57.5 (20.3) [73] 54.7 (19.2) [67] 59.3 (19.9) [85] 62.4 (20.3) [90] 0.07
EQ-5D-5L index-value: scale from - 0.28 to 1.0. EORTC-QLQ-C30/BR23 and BREAST-Q scale 0 to 100
Higher scores represent higher quality
±Higher scores represent lower quality
[] percentages complete modules if not 100%
¥ANOVA
*Statistically significant differences
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TABLE 3 Multivariate linear regression analyses in 612 primary breast cancer patients
EORTC-QLQ-C30 EORTC-QLQ-BR23 BREAST-Q
Physical
functioning
Body image Sexual functioning Q-physical Q-psychosocial Q-satisfaction with
breast
b p value b p value b p value b p value b p value b p value
Operation type
BCT ref Na ref Na ref Na ref Na ref Na ref Na
MAS - 3.781 0.27 - 7.757 0.15 - 8.185 0.10 - 0.253 0.95 - 2.620 0.57 - 13.596 0.003*
REC I 5.223 0.15 - 4.033 0.48 2.544 0.64 2.579 0.53 6.365 0.18 - 13.040 0.007*
REC A 0.523 0.89 1.084 0.85 - 0.881 0.87 4.712 0.26 9.434 0.05 - 2.651 0.59
Age - 0.259 \0.001* 0.209 0.02 - 0.427 \ 0.001* 0.095 0.13 0.090 0.22 0.097 0.19
Time since
surgery
0.252 0.14 0.572 0.03 - 0.473 0.06 0.446 0.02 0.299 0.19 - 0.059 0.79
Surgery
Unilateral ref Na ref Na ref Na ref Na ref Na ref Na
Bilateral - 3.560 0.08 1.729 0.59 2.349 0.44 - 3.732 0.11 2.888 0.28 - 0.327 0.90
T stage
T1 ref Na ref Na ref Na ref Na ref Na ref Na
T2 1.481 0.36 - 1.757 0.51 - 2.595 0.31 0.1997 0.92 - 2.343 0.30 - 2.122 0.33
T3 - 2.700 0.48 - 1.324 0.82 - 2908 0.60 - 0.761 0.86 - 1.267 0.80 1.765 0.73
CIS 2.026 0.28 0.836 0.27 4.363 0.03 2.930 0.17 2.007 0.42 0.657 0.79
Unknown 5.721 0.59 Na Na - 8.785 0.12 - 0.833 0.95 - 7.227 0.61 - 1.205 0.93
N stage
N0 ref Na ref Na ref Na ref Na ref Na ref Na
N? 1.096 0.52 - 0.949 0.73 6.281 0.02 2.179 0.26 2.036 0.37 - 4.348 0.06
Systemic therapy
None ref Na ref Na ref Na ref Na ref Na ref Na
CTx - 2.658 0.25 - 2.189 0.55 3.586 0.31 - 1.953 0.47 - 4.660 0.14 1.281 0.68
ETx - 4.394 0.03 1.402 0.66 - 2.850 0.36 0.201 0.93 4.366 0.11 2.341 0.39
CTx & ETx - 0.246 0.90 1.433 0.65 2.442 0.42 0.053 0.98 3.199 0.23 2.638 0.32
Radiation therapy
RTx
following
BCS
ref Na ref Na ref Na ref Na ref Na ref Na
No RTx - 1.693 0.62 - 1.144 0.83 4.617 0.36 5.290 0.17 - 3.956 0.38 11.956 0.009*
Thoracic wall
and/or
locoregional
RTx
- 5.323 0.13 - 2.702 0.63 2.890 0.58 - 3.017 0.46 - 4.903 0.30 8.860 0.07
BRCA
BRCA1/2
negative
ref Na ref Na ref Na ref Na ref Na ref Na
BRCA1/2
positive
4.602 0.04 - 5.429 0.13 - 1.371 0.69 1.454 0.58 - 3.997 0.19 - 5.242 0.09
Unknown - 0.437 0.78 - 2.408 0.34 1.653 0.49 - 2.311 0.20 - 4.516 0.03 - 0.969 0.65
The multivariable linear regression model was composed of all baseline characteristics present in the left column of the table
BCT breast-conserving therapy, MAS mastectomy, REC I mastectomy followed by (in)direct implant reconstruction, REC A mastectomy
followed by (in)direct autologous reconstruction, CTx chemotherapy and/or immunotherapy, ETx endocrine therapy, RTx radiation therapy
*Significant beta coefficient
Higher scores represent higher quality
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data could be used to build models to perform case-mix
analyses which could be validated in other cohorts. The
response rate for sexual functioning (EORTC-QLQ-BR23)
was lower compared with other PROs, except for patients
with breast reconstruction. Therefore, scores for sexual
functioning might have been biased. Previous studies on
sexual health in breast cancer patients showed that 50–90%
of women experience sexual dysfunction19,20 and that
breast cancer surgery has a negative impact.21 The VBHC
initiative, with questions regarding sexual functioning,
could possibly open up the conversation and future con-
sultation on sexuality in breast cancer patients at the
outpatient clinic. Data on sexual functioning are hampered
by the lower response rate and the lack of longitudinal data,
limiting the clinical applicability of these scores.
There were no statistically significant differences in
PROs between PBC and SBC patients. This conclusion is
hampered concerning the BREAST-Q questionnaire. In the
SBC group, in which patients are more often operated on
both breasts, the applicability of the BREAST-Q is lower,
since it does not account for two operated breasts or dif-
ferent types of breast surgery.
Measuring PROs during treatment has the potential to
monitor and detect changes in physical or psychosocial
problems at the outpatient clinic. Consequently, targeted
supportive care concerning health-related QoL may be
provided and possibly improve the care delivered.9,22 This
evaluation enables a first insight into PRO scores according
to patient, tumor, and treatment characteristics. Reference
scores for the different PROs are pivotal when PROs are
being used at the outpatient clinic to tailor and improve the
care delivered. Knowledge on differences in satisfaction
scores per type of breast cancer surgery performed can be
used for shared decision-making.16 However, it should be
stressed that we cannot determine a causal relation between
the different treatments and outcome yet. Effects of treat-
ments in observational data are potentially biased by
confounding by indication and selection and should be
interpreted with caution. Prospective and repeated evalua-
tions of PROs throughout care form the cornerstone of
VBHC and potentially enable more patient-centered breast
cancer care with the possibility of improved shared treat-
ment decision-making in breast cancer patients.
CONCLUSIONS
PROs were evaluated in 764 historical patients accord-
ing to patient, tumor, and treatment characteristics in a
single center. ‘‘Satisfaction with breasts’’ differed between
type of surgery delivered. This knowledge as well as the
collection of reference values could add value in shared
decision-making concerning breast cancer surgery.
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